5.185
Solid Biosciences Inc stock is traded at $5.185, with a volume of 989.37K.
It is down -3.80% in the last 24 hours and down -12.12% over the past month.
Solid Biosciences Inc is a life science company. It is engaged in the manufacturing of specialty and generic drugs. The company is involved in curing Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease predominantly affecting boys, with symptoms that usually manifest between three and five years of age. The company's pipeline products are the SB-001 and solid suit. The Company's singular focus is on developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases. The company has categorized its programs into corrective therapies, disease-modifying therapies, and assistive devices.
See More
Previous Close:
$5.39
Open:
$5.35
24h Volume:
989.37K
Relative Volume:
0.97
Market Cap:
$403.75M
Revenue:
$14.79M
Net Income/Loss:
$-102.44M
P/E Ratio:
-1.7056
EPS:
-3.04
Net Cash Flow:
$-91.73M
1W Performance:
-12.12%
1M Performance:
-12.12%
6M Performance:
+20.30%
1Y Performance:
-9.83%
Solid Biosciences Inc Stock (SLDB) Company Profile
Name
Solid Biosciences Inc
Sector
Industry
Phone
617-337-4680
Address
500 RUTHERFORD AVENUE, CHARLESTOWN, MA
Compare SLDB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
SLDB
Solid Biosciences Inc
|
5.185 | 419.71M | 14.79M | -102.44M | -91.73M | -3.04 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.41 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.28 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.39 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
821.96 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
183.80 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Solid Biosciences Inc Stock (SLDB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-26-25 | Initiated | Citigroup | Buy |
| Jan-08-25 | Initiated | Truist | Buy |
| Dec-13-24 | Initiated | Wedbush | Outperform |
| Dec-10-24 | Initiated | JMP Securities | Mkt Outperform |
| Jul-15-24 | Upgrade | JP Morgan | Neutral → Overweight |
| Jun-24-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| May-31-24 | Resumed | Piper Sandler | Overweight |
| Mar-28-24 | Initiated | William Blair | Outperform |
| Mar-15-24 | Initiated | Citigroup | Buy |
| Mar-14-24 | Upgrade | Piper Sandler | Neutral → Overweight |
| Dec-08-23 | Initiated | H.C. Wainwright | Buy |
| Jul-12-21 | Initiated | Piper Sandler | Neutral |
| May-27-21 | Initiated | Jefferies | Buy |
| Mar-16-21 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Mar-09-21 | Initiated | Barclays | Overweight |
| Jan-08-21 | Upgrade | Credit Suisse | Underperform → Neutral |
| Jul-28-20 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| May-07-20 | Downgrade | Evercore ISI | Outperform → In-line |
| Oct-11-19 | Initiated | Evercore ISI | Outperform |
| Aug-29-19 | Downgrade | Citigroup | Neutral → Sell |
| Aug-19-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Aug-16-19 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| May-14-19 | Downgrade | Credit Suisse | Neutral → Underperform |
| May-14-19 | Downgrade | Goldman | Neutral → Sell |
| Feb-08-19 | Upgrade | Citigroup | Sell → Neutral |
| Feb-08-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Nov-06-18 | Initiated | Citigroup | Sell |
| Sep-06-18 | Initiated | Credit Suisse | Neutral |
View All
Solid Biosciences Inc Stock (SLDB) Latest News
Does Solid Biosciences Inc. stock trade at a discount to peersDip Buying & Stock Portfolio Risk Management - newser.com
What’s next for Solid Biosciences Inc. stock price2025 Top Gainers & Community Verified Trade Signals - newser.com
Strategies to average down on Solid Biosciences Inc.2025 AllTime Highs & Safe Capital Growth Trade Ideas - newser.com
Is Solid Biosciences Inc. stock positioned for long term growthMarket Growth Summary & Free Weekly Chart Analysis and Trade Guides - newser.com
Is Solid Biosciences Inc. stock in correction or buying zoneQuarterly Earnings Report & Consistent Profit Focused Trading Strategies - newser.com
How to monitor Solid Biosciences Inc. with trend dashboardsTrade Volume Summary & Advanced Technical Analysis Signals - newser.com
What insider trading reveals about Solid Biosciences Inc. stockJuly 2025 Rallies & Fast Exit and Entry Strategy Plans - newser.com
What momentum indicators show for Solid Biosciences Inc. stock2025 Retail Activity & Real-Time Price Movement Reports - newser.com
Can Solid Biosciences Inc. stock beat analyst upgradesFed Meeting & Weekly Momentum Picks - newser.com
Why Solid Biosciences Inc. stock is trending among retail tradersJuly 2025 Price Swings & Expert Curated Trade Setup Alerts - newser.com
Using flow based indicators on Solid Biosciences Inc.2025 Trade Ideas & Low Drawdown Trading Strategies - newser.com
Using Bollinger Bands to evaluate Solid Biosciences Inc.July 2025 Institutional & Fast Gain Stock Trading Tips - newser.com
Predicting Solid Biosciences Inc. trend using moving averagesJuly 2025 Final Week & Proven Capital Preservation Tips - newser.com
Solid Biosciences Inc expected to post a loss of 44 cents a shareEarnings Preview - TradingView
How sustainable is Solid Biosciences Inc. stock dividend payoutWeekly Profit Analysis & Reliable Volume Spike Alerts - newser.com
Will Solid Biosciences Inc. stock reach all time highs in 20252025 Trading Volume Trends & Safe Entry Momentum Stock Tips - newser.com
Applying sector rotation models to Solid Biosciences Inc.Portfolio Performance Summary & Weekly Market Pulse Alerts - newser.com
Solid Biosciences to Participate at Upcoming Investor Conferences - Stock Titan
Solid Biosciences (SLDB) Projected to Post Earnings on Wednesday - MarketBeat
Solid Biosciences Inc Stock (SLDB) Financials Data
Revenue
Net Income
Cash Flow
EPS
Solid Biosciences Inc Stock (SLDB) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Kahn Clare | Director |
Mar 11 '25 |
Buy |
5.34 |
1,860 |
9,924 |
2,960 |
| Bain Capital Life Sciences Inv | 10% Owner |
Feb 19 '25 |
Buy |
4.03 |
1,000,000 |
4,030,000 |
5,034,582 |
| PERCEPTIVE ADVISORS LLC | Director |
Feb 19 '25 |
Buy |
4.03 |
5,000,000 |
20,150,000 |
11,833,539 |
| Adage Capital Management, L.P. | 10% Owner |
Feb 18 '25 |
Buy |
7.56 |
252,545 |
1,909,240 |
4,248,084 |
| Hanrahan Jessie | Chief Regulatory Officer |
Feb 14 '25 |
Sale |
3.96 |
3,079 |
12,193 |
19,281 |
| Brooks Gabriel | Chief Medical Officer |
Feb 14 '25 |
Sale |
3.96 |
3,256 |
12,894 |
22,812 |
| Tan Kevin | CFO & Treasurer |
Feb 14 '25 |
Sale |
3.96 |
3,164 |
12,529 |
32,250 |
| Howton David T | Chief Operating Officer |
Feb 14 '25 |
Sale |
3.96 |
5,561 |
22,022 |
24,789 |
| Herzich Paul | Chief Technology Officer |
Feb 14 '25 |
Sale |
3.96 |
2,688 |
10,644 |
18,388 |
| Cumbo Alexander | President and CEO |
Feb 14 '25 |
Sale |
3.96 |
11,365 |
45,005 |
60,717 |
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):